Dana-Farber Brigham Cancer Center (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
146
Publications
2438
Citations
123916
i10-index
880
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
The Immune Landscape of Cancer | 2018 | 5832 |
Nivolumab versus Everolimus in Advanced Renal-Cell... | 2015 | 5746 |
Post-acute COVID-19 syndrome | 2021 | 4754 |
Nivolumab plus Ipilimumab versus Sunitinib in Adva... | 2018 | 4403 |
Pembrolizumab as Second-Line Therapy for Advanced ... | 2017 | 3267 |
Avelumab plus Axitinib versus Sunitinib for Advanc... | 2019 | 2439 |
Prognostic Factors for Overall Survival in Patient... | 2009 | 2064 |
Pazopanib versus Sunitinib in Metastatic Renal-Cel... | 2013 | 1882 |
Clinical impact of COVID-19 on patients with cance... | 2020 | 1766 |
Lenvatinib plus Pembrolizumab or Everolimus for Ad... | 2021 | 1597 |
Toni K. Choueiri is a researcher with 2438 publications and 123916 citations. They are affiliated with Dana-Farber Brigham Cancer Center. Their research focuses on . With an h-index of 146, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Toni K. Choueiri and 250M+ other papers.
Citations per publication by year